Home » Topics » BioWorld Science

BioWorld Science
RSS

Flamingo and Ionis expand alliance to develop RNA-targeted therapies for oncology

Sep. 10, 2021

STM-2457: a first-in-class METTL3 inhibitor with preclinical proof of concept in AML models

Sep. 10, 2021

PearlRiverBio patents mutant EGFR/HER2 inhibitors

Sep. 10, 2021

HA-344 shows promise for treating cutaneous metastatic melanoma

Sep. 10, 2021

Novel virulence factor LasB inhibitors for the treatment of P. aeruginosa infections

Sep. 10, 2021

Discovery of novel antibiotic class of tethered macrocyclic peptides

Sep. 10, 2021

New PIKfyve inhibitors identified at AcuraStem

Sep. 10, 2021

Salk Institute, Sanford Burnham Prebys describe new ULK1 inhibitors

Sep. 10, 2021

StemSynergy Therapeutics patents N-myc proto-oncogene protein inhibitors

Sep. 10, 2021

Small-molecule OXS-7417 shows in vivo AML antitumoral effects

Sep. 10, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...